Curtis, J. R., Xie, F., Kay, J., & Kallich, J. D. (2019). Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther.
Chicago Stili AlıntıCurtis, Jeffrey R., Fenglong Xie, Jonathan Kay, ve Joel D. Kallich. "Will Savings From Biosimilars Offset Increased Costs Related to Dose Escalation? A Comparison of Infliximab and Golimumab for Rheumatoid Arthritis." Arthritis Res Ther 2019.
MLA AlıntıCurtis, Jeffrey R., Fenglong Xie, Jonathan Kay, ve Joel D. Kallich. "Will Savings From Biosimilars Offset Increased Costs Related to Dose Escalation? A Comparison of Infliximab and Golimumab for Rheumatoid Arthritis." Arthritis Res Ther 2019.